Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269

The Meningococcal Antigen Typing System (MATS) has been developed as an hSBA surrogate to evaluate potential coverage afforded by the 4-component meningococcal serogroup B vaccine (4CMenB: Bexsero, GSK). We investigated whether the lower value of MATS coverage among invasive Meningococcus serogroup...

Full description

Bibliographic Details
Main Authors: Maria Stella, Maria Giuliani, Alessia Biolchi, Sara Tomei, Rosita De Paola, Xilian Bai, Ray Borrow, Jay Lucidarme, Rita La Gaetana, Daniela Toneatto, Mariagrazia Pizza, Laura Serino, Elena Mori, Marzia Monica Giuliani
Format: Article
Language:English
Published: Taylor & Francis Group 2020-04-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
neisseria meningitidis
meningococcus serogroup b
meningococcal b vaccine
4cmenb
meningococcal antigen typing system
serum bactericidal antibody assay
Online Access:http://dx.doi.org/10.1080/21645515.2019.1688039

Internet

http://dx.doi.org/10.1080/21645515.2019.1688039

Similar Items